vs
安进（AMGN）与登士柏西诺德（XRAY）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是登士柏西诺德的10.3倍（$9.9B vs $961.0M）。安进净利率更高（13.5% vs -15.2%，领先28.7%）。安进同比增速更快（8.6% vs 6.2%）。安进自由现金流更多（$961.0M vs $60.0M）。过去两年安进的营收复合增速更高（15.1% vs 0.4%）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
登士柏西诺德是美国牙科设备及耗材制造商，业务覆盖全球120多个国家，在21个国家设有生产工厂。该公司前身为1993年Gendex公司以5.9亿美元收购登士柏国际后整合组建的企业，是全球牙科领域的重要供应商。
AMGN vs XRAY — 直观对比
营收规模更大
AMGN
是对方的10.3倍
$961.0M
营收增速更快
AMGN
高出2.4%
6.2%
净利率更高
AMGN
高出28.7%
-15.2%
自由现金流更多
AMGN
多$901.0M
$60.0M
两年增速更快
AMGN
近两年复合增速
0.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $961.0M |
| 净利润 | $1.3B | $-146.0M |
| 毛利率 | 69.8% | 46.1% |
| 营业利润率 | 27.6% | -14.5% |
| 净利率 | 13.5% | -15.2% |
| 营收同比 | 8.6% | 6.2% |
| 净利润同比 | 112.6% | 66.0% |
| 每股收益（稀释后） | $2.45 | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNXRAY
| Q4 25 | $9.9B | $961.0M | ||
| Q3 25 | $9.6B | $904.0M | ||
| Q2 25 | $9.2B | $936.0M | ||
| Q1 25 | $8.1B | $879.0M | ||
| Q4 24 | $9.1B | $905.0M | ||
| Q3 24 | $8.5B | $951.0M | ||
| Q2 24 | $8.4B | $984.0M | ||
| Q1 24 | $7.4B | $953.0M |
净利润AMGNXRAY
| Q4 25 | $1.3B | $-146.0M | ||
| Q3 25 | $3.2B | $-427.0M | ||
| Q2 25 | $1.4B | $-45.0M | ||
| Q1 25 | $1.7B | $20.0M | ||
| Q4 24 | $627.0M | $-430.0M | ||
| Q3 24 | $2.8B | $-494.0M | ||
| Q2 24 | $746.0M | $-4.0M | ||
| Q1 24 | $-113.0M | $18.0M |
毛利率AMGNXRAY
| Q4 25 | 69.8% | 46.1% | ||
| Q3 25 | 67.8% | 48.8% | ||
| Q2 25 | 67.2% | 52.4% | ||
| Q1 25 | 63.6% | 53.0% | ||
| Q4 24 | 65.7% | 49.3% | ||
| Q3 24 | 61.1% | 52.1% | ||
| Q2 24 | 61.4% | 51.9% | ||
| Q1 24 | 57.0% | 53.1% |
营业利润率AMGNXRAY
| Q4 25 | 27.6% | -14.5% | ||
| Q3 25 | 26.4% | -24.1% | ||
| Q2 25 | 28.9% | -13.7% | ||
| Q1 25 | 14.5% | 7.2% | ||
| Q4 24 | 25.4% | -56.2% | ||
| Q3 24 | 24.1% | -48.6% | ||
| Q2 24 | 22.8% | 5.1% | ||
| Q1 24 | 13.3% | 4.4% |
净利率AMGNXRAY
| Q4 25 | 13.5% | -15.2% | ||
| Q3 25 | 33.7% | -47.2% | ||
| Q2 25 | 15.6% | -4.8% | ||
| Q1 25 | 21.2% | 2.3% | ||
| Q4 24 | 6.9% | -47.5% | ||
| Q3 24 | 33.3% | -51.9% | ||
| Q2 24 | 8.9% | -0.4% | ||
| Q1 24 | -1.5% | 1.9% |
每股收益（稀释后）AMGNXRAY
| Q4 25 | $2.45 | $-0.74 | ||
| Q3 25 | $5.93 | $-2.14 | ||
| Q2 25 | $2.65 | $-0.22 | ||
| Q1 25 | $3.20 | $0.10 | ||
| Q4 24 | $1.17 | $-2.09 | ||
| Q3 24 | $5.22 | $-2.46 | ||
| Q2 24 | $1.38 | $-0.02 | ||
| Q1 24 | $-0.21 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | $326.0M |
| 总债务越低越好 | $54.6B | $2.3B |
| 股东权益账面价值 | $8.7B | $1.3B |
| 总资产 | $90.6B | $5.4B |
| 负债/权益比越低杠杆越低 | 6.31× | 1.70× |
8季度趋势，按日历期对齐
现金及短期投资AMGNXRAY
| Q4 25 | $9.1B | $326.0M | ||
| Q3 25 | $9.4B | $363.0M | ||
| Q2 25 | $8.0B | $359.0M | ||
| Q1 25 | $8.8B | $398.0M | ||
| Q4 24 | $12.0B | $272.0M | ||
| Q3 24 | $9.0B | $296.0M | ||
| Q2 24 | $9.3B | $279.0M | ||
| Q1 24 | $9.7B | $291.0M |
总债务AMGNXRAY
| Q4 25 | $54.6B | $2.3B | ||
| Q3 25 | $54.6B | — | ||
| Q2 25 | $56.2B | — | ||
| Q1 25 | $57.4B | — | ||
| Q4 24 | $60.1B | $1.7B | ||
| Q3 24 | $60.4B | — | ||
| Q2 24 | $62.6B | — | ||
| Q1 24 | $64.0B | — |
股东权益AMGNXRAY
| Q4 25 | $8.7B | $1.3B | ||
| Q3 25 | $9.6B | $1.5B | ||
| Q2 25 | $7.4B | $2.0B | ||
| Q1 25 | $6.2B | $2.0B | ||
| Q4 24 | $5.9B | $1.9B | ||
| Q3 24 | $7.5B | $2.5B | ||
| Q2 24 | $5.9B | $3.1B | ||
| Q1 24 | $5.0B | $3.3B |
总资产AMGNXRAY
| Q4 25 | $90.6B | $5.4B | ||
| Q3 25 | $90.1B | $5.7B | ||
| Q2 25 | $87.9B | $6.1B | ||
| Q1 25 | $89.4B | $6.0B | ||
| Q4 24 | $91.8B | $5.8B | ||
| Q3 24 | $90.9B | $6.6B | ||
| Q2 24 | $90.9B | $6.9B | ||
| Q1 24 | $93.0B | $7.1B |
负债/权益比AMGNXRAY
| Q4 25 | 6.31× | 1.70× | ||
| Q3 25 | 5.67× | — | ||
| Q2 25 | 7.57× | — | ||
| Q1 25 | 9.24× | — | ||
| Q4 24 | 10.23× | 0.90× | ||
| Q3 24 | 8.02× | — | ||
| Q2 24 | 10.57× | — | ||
| Q1 24 | 12.75× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $101.0M |
| 自由现金流经营现金流 - 资本支出 | $961.0M | $60.0M |
| 自由现金流率自由现金流/营收 | 9.7% | 6.2% |
| 资本支出强度资本支出/营收 | 6.5% | 4.3% |
| 现金转化率经营现金流/净利润 | 1.20× | — |
| 过去12个月自由现金流最近4个季度 | $8.1B | $104.0M |
8季度趋势，按日历期对齐
经营现金流AMGNXRAY
| Q4 25 | $1.6B | $101.0M | ||
| Q3 25 | $4.7B | $79.0M | ||
| Q2 25 | $2.3B | $48.0M | ||
| Q1 25 | $1.4B | $7.0M | ||
| Q4 24 | $4.8B | $87.0M | ||
| Q3 24 | $3.6B | $141.0M | ||
| Q2 24 | $2.5B | $208.0M | ||
| Q1 24 | $689.0M | $25.0M |
自由现金流AMGNXRAY
| Q4 25 | $961.0M | $60.0M | ||
| Q3 25 | $4.2B | $40.0M | ||
| Q2 25 | $1.9B | $16.0M | ||
| Q1 25 | $980.0M | $-12.0M | ||
| Q4 24 | $4.4B | $36.0M | ||
| Q3 24 | $3.3B | $98.0M | ||
| Q2 24 | $2.2B | $156.0M | ||
| Q1 24 | $459.0M | $-9.0M |
自由现金流率AMGNXRAY
| Q4 25 | 9.7% | 6.2% | ||
| Q3 25 | 44.4% | 4.4% | ||
| Q2 25 | 20.8% | 1.7% | ||
| Q1 25 | 12.0% | -1.4% | ||
| Q4 24 | 48.4% | 4.0% | ||
| Q3 24 | 39.0% | 10.3% | ||
| Q2 24 | 26.5% | 15.9% | ||
| Q1 24 | 6.2% | -0.9% |
资本支出强度AMGNXRAY
| Q4 25 | 6.5% | 4.3% | ||
| Q3 25 | 4.6% | 4.3% | ||
| Q2 25 | 4.0% | 3.4% | ||
| Q1 25 | 5.0% | 2.2% | ||
| Q4 24 | 4.1% | 5.6% | ||
| Q3 24 | 3.0% | 4.5% | ||
| Q2 24 | 2.8% | 5.3% | ||
| Q1 24 | 3.1% | 3.6% |
现金转化率AMGNXRAY
| Q4 25 | 1.20× | — | ||
| Q3 25 | 1.46× | — | ||
| Q2 25 | 1.59× | — | ||
| Q1 25 | 0.80× | 0.35× | ||
| Q4 24 | 7.61× | — | ||
| Q3 24 | 1.26× | — | ||
| Q2 24 | 3.30× | — | ||
| Q1 24 | — | 1.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
XRAY
| Essential Dental Solutions | $372.0M | 39% |
| Equipment And Instruments | $160.0M | 17% |
| Implants And Prosthetics | $150.0M | 16% |
| CADCAM | $139.0M | 14% |
| Wellspect Healthcare | $88.0M | 9% |
| Orthodontics | $52.0M | 5% |
